Received 21.06.2023
DOI: 10.35556/idr-2023-3(104)4-8
Medication-related osteonecrosis of the jaws associated with the use of bone-modifying agents: new studies
Shelegova I.G., ORCHID ID: 0000-0002-8381-2535, Nurieva N.S., ORCHID ID: 0000-0002-5656-2286
Federal State Budgetary Educational Institution of Higher Education “South-Urals State Medical University” of the Ministry of Health of the Russian Federation
454020, Russia, Chelyabinsk, Vorovskogo St., 38b

E-mail address: irina-stomat@rambler.ru

Summary
The relevance of the study is associated with the widespread use of osteomodifying agents in patients with bone metastases and osteoporosis. A serious complication associated with the use of bisphosphonates and other osteomodifying agents is known — medical osteonecrosis of the jaws, but the pathogenesis of this disease has not been fully studied. With drug-induced osteonecrosis of the jaws in oncological patients with bone metastases, therapy with osteomodifying agents is suspended, which can cause a decrease in the patient’s life span. This is due to the importance of prevention, early diagnosis, and rapid treatment of patients with drug-induced osteonecosis. The aim of the work was to analyze the studies carried out in 2021—2023 on new methods of diagnosis, treatment, prevention of medical osteonecrosis of the jaws. The literature review is based on the analysis of published studies according to the PubMed electronic resource.
The analysis of the literature data showed that bisphosphonates and other osteomodifying agents are widely used in oncology and the profile of age-related changes in the human bone system. The use, therapeutic effects and complications of therapy with osteomonefying agents are being investigated all over the world. Cone-beam computed tomography remains the “gold standard” in the diagnosis of medicamental osteonecrosis of people. Antibiotic therapy is considered as an effective method of treatment. It is proposed to use hyperbaric oxygenation, laser treatment, bone resection under fluorescence control, photodynamic therapy, introduction of a biomaterial based on tricalcium phosphate, administration of teriparatide and atorvastatin as additional treatment methods. Regular dental examinations are the most effective means of preventing drug-induced osteonecrosis. The study of pathogenesis, new methods of therapy and prevention of drug-induced osteonecrosis of the jaws remains urgent.

Keywords: bone-modifying agents, bisphosphonates, bone metastases, osteoporosis, medication-related osteonecrosis of the jaw.

For citation: Shelegova I.G., Nurieva N.S. Medication-related osteonecrosis of the jaws associated with the use of bone-modifying agents: new studies. Stomatology for All / Int. Dental Review. 2023; no.3(104): 4-8 (in Russian). doi: 10.35556/idr-2023-3(104)4-8

References
1. Ruggiero S.L., Dodson T.B., Aghaloo T., Carlson E.R., Ward B.B., Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022 May; 80(5): 920—943. doi: 10.1016/j.joms.2022.02.008
2. Matys T. Medication-related Osteonecrosis of the Jaw. Radiology. 2021 Dec; 301(3): 548 p. doi: 10.1148/radiol.2021211142
3. Ruggiero S.L., Dodson T.B., Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014; 72(10): 1938—1956. doi: 10.1016/j.joms.2022.02.008
4. Ozkan E., Bereket M.C., Ozkan N. Knowledge and attitude regarding bisphosphonates and related osteonecrosis among Turkish dentist: A cross sectional study. Niger J Clin Pract. 2021 Oct; 24(10): 1485—1491. doi: 10.4103/njcp.njcp_684_20
5. Firincioglulari M, Orhan K. Teledentistry as a Supportive Tool for Dentists in Diagnosing MRONJ in Northern Cyprus. BioMed Research International. 2021. doi: 10.1155/2021/5657152
6. Ito K., Muraoka H., Hirahara N., Sawada E., Hirohata S., Otsuka K., et al. Quantitative assessment of mandibular bone marrow using computed tomography texture analysis for detect stage 0 medication-related osteonecrosis of the jaw. Eur J Radiol. 2021 Dec; 145: 110030. doi: 10.1016/j.ejrad.2021.110030
7. Omami G. Medication-Related Osteonecrosis of the Mandible. Ear Nose Throat J. 2021 Sep; 100(8): NP366—NP367. doi: 10.1177/0145561320919574
8. Baba A., Goto T.K., Ojiri H. et al. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol. 2018; 47(4): 20170323. doi: 10.1259/dmfr.20170323
9. Bonachea R., Katz J. Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review. Am J Dent. 2022 Apr; 35(2): 109—112.
10. Mauceri R., Coniglio R., Abbinante A., Carcieri P., Tomassi D., Panzarella V., et al. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. 2022 Aug; 30(8): 6429—6440. doi: 10.1007/s00520-022-06940-8
11. Khan I. MRONJ and ENT. Br Dent J. 2022 May; 232(10): 675 p. doi: 10.1038/s41415-022-4304-9
12. Ogawa R., Ogura I. Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value. Dentomaxillofac Radiol. 2021 Dec; 50(8): 20200516. doi: 10.1259/dmfr.20200516
13. Aoki K., Matsunaga S., Ito S., Shibahara T., Nomura T., Matsuzaki H., et al. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis. J Bone Miner Metab. 2021 Sep; 39(5): 737—747. doi: 10.1007/s00774-021-01223-4
14. Hadad H., Kawamata de Jesus L., Piquera Santos A.F., Rinaldi Matheus H., de Souza Rodrigues L.G., Paolo Poli P., et al. Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw. Scientific reports. 2022; 12(1): 16510. doi: 10.1038/s41598-022-20128-4
15. Dos Santos Ferreira L., Abreu L.G., Calderipe C.B., Martins M.D., Schuch L.F., Vasconcelos ACU. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporos Int. 2021 Dec; 32(12): 2449—2459. doi: 10.1007/s00198-021-06078-z
16. De Sousa V.C., Sousa N.F.R., Vasconcelos R.F., Martins C.S., Lopes A.P., Alves N.M., et al. Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats. Bone. 2022; 164: 116523. doi: 10.1016/j.bone.2022.116523
17. Pazianas M. Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats. Bone. 2022; 165: 116561. doi: 10.1016/j.bone.2022.116561
18. Schubert L., Russmueller G., Lagler H., Tobudic S., Heindel E., Kundi M., et al. Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw. Support Care Cancer. 2021 Dec; 29(12): 7895—7902. doi: 10.1007/s00520-021-06361-z
19. Wei L.Y., Kok S.H., Lee Y.C., et al. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients. Oral Dis. 2022 Jan; 28(1): 182—192. doi: 10.1111/odi.13737
20. Wei L.Y., Kok S.H., Lee Y.C., Chiu W.Y., Wang J.J., Cheng S.J., et al. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid. J Journal of the Formosan Medical Association 2021 Aug; 120(8): 1572—1580. doi: 10.1016/j.jfma.2020.11.017
21. Ciobanu G.A., Camen A., Ionescu M., Vlad D., Munteanu C.M., Gheorghiță M.I., et al. Risk factors for medication-related osteonecrosis of the Jaw-A binomial analysis of data of cancer patients from craiova and constanta treated with zoledronic acid. Journal of clinical medicine. 2023; 12(11): 3747. doi: 10.3390/jcm12113747
22. Martins F., Macedo D., Palma L.F., Ortega K.L., Campos L. Photobiomodulation and antimicrobial photodynamic therapy for the prevention of osteonecrosis of the jaw in an oncologic patient. Photodiagnosis Photodyn Ther. 2021 Dec; 36: 102587. doi: 10.1016/j.pdpdt.2021.102587
23. Sanchez-Gallego Albertos C., Del Castillo Pardo de Vera J.L., Viejo Llorente A., Cebrian Carretero J.L. Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement. Med Oral Patol Oral Cir Bucal. 2021 Nov; 26(6): 684—690. doi: 10.4317/medoral.24007
24. Park W.B., Herr Y., Kwon Y.D., Shin S.I., Lim H.C. Advanced peri-implantitis and implant removal as risk factors for osteonecrosis of the jaw in patients on oral bisphosphonate therapy. J Oral Implantol. 2021 Oct; 47(5): 420—426. doi: 10.1563/aaid-joi-D-20-00298
25. Beth-Tasdogan N.H., Mayer B., Hussein H., Zolk O., Peter J.U. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022 Jul; 7(7): CD012432. doi: 10.1002/14651858.CD012432.pub3
26. Hasegawa T., Ueda N., Yamada SI., Kato S., Iwata E., Hayashida S., et al. Japanese Study Group of Co-operative Dentistry with Medicine (JCDM). Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study. Osteoporos Int. 2021 Nov; 32(11): 2323—2333. doi: 10.1007/s00198-021-05995-3
27. Park J.H., Cho S., Kim S.J., Jeong T.D., Mun Y.C., Kim J.W. Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study. Osteoporos Int. 2022 Feb; 33(2): 367—377. doi: 10.1007/s00198-021-06137-5
28. Varidel A., Wong E. Conservative Management of Severe Medication-Related Osteonecrosis of the Jaw With Pathological Fracture. J Craniofac Surg. 2022 May; 33(3): e329—e333. doi: 10.1097/SCS.0000000000008222
29. Yoshizawa K., Moroi A., Iguchi R., Takayama A., Goto J., Takayama Y., et al. An unusual case of bone regeneration of a necrotic mandible with pathologic fracture in an elderly hemodialysis patient with medication-related osteonecrosis of the jaw: a case report and review of the literature. J Med Case Rep. 2021 Dec; 15(1): 608. doi: 10.1186/s13256-021-03206-5
30. Yan R., Jiang R., Hu L., Deng Y., Wen J., Jiang X. Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ). Int J Oral Sci. 2022 Aug; 14(1): 41. doi: 10.1038/s41368-022-00182-4
31. Sanda K., Ayukawa Y., Yasunami N., Adachi N., Furuhashi A., Imai M., et al. Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw. J Periodontol. 2022 Jun; 93(6): 837—846. doi: 10.1002/JPER.21-0294
32. Sharma D., Hamlet S., Vaquette C., Petcu E.B., Ramamurthy P., Ivanovski S. Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw. Sci Rep. 2021 Dec; 11(1): 23371. doi: 10.1038/s41598-021-02637-w
33. Yu R.Q., Li J.W., Wang J.Y., Huo L., Zheng L.W. Effects of Soft Tissue Closure on Medication-Related Osteonecrosis of the Jaw in a Rabbit Model with Tooth Extraction: A Pilot Study. Biomed Res Int. 2021 Dec; 15: 4166770. doi: 10.1155/2021/4166770
34. Monteiro C.G.J., Vieira E.M., Emerick C., Azevedo R.S., Pascoal V.A.B., Homsi N., et al. Ozonated oil effect for prevention of medication-related osteonecrosis of the jaw (MRONJ) in rats undergoing zoledronic acid therapy. Clin Oral Investig. 2021 Dec; 25(12): 6653—6659. doi: 10.1007/s00784-021-03951-3
35. Du W., Yang M., Kim T., Kim S., Williams D.W., Esmaeili M., et al. Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice. Int J Oral Sci. 2022 Mar; 14(1): 16. doi: 10.1038/s41368-022-00166-4
36. Soma T., Iwasaki R., Sato Y., Kobayashi T., Ito E., Matsumoto T., et al. Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics. Sci Rep. 2022 Jan; 12(1): 19. doi: 10.1038/s41598-021-03966-6
37. Delfrate G., Mroczek T., Mecca L.E.A., Andreis J.D., Fernandes D., Lipinski L.C., et al. Effect of pentoxifylline and -tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction. Arch Oral Biol. 2022 May; 137: 105397. doi: 10.1016/j.archoralbio.2022.105397
38. Pan W., Gu J., Xu S., Zhang C., Wang J., Wang S., et al. Dietary nitrate improves jaw bone remodelling in zoledronate-treated mice. Cell proliferation, 2023; e13395. doi: 10.1111/cpr.13395
39. Moradi S., Razavi B.M., Moushekhian S., Pourmahmoud N., Marvi M. Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: A Histological Evaluation. Journal of dentistry (Shiraz, Iran). 2023; 24(1): 41—46. doi: 10.30476/DENTJODS.2022.91452.1583
40. Williams D. W., Ho K., Lenon A., Kim S., Kim T., Gwack Y., et al. Long-Term Ligature-Induced Periodontitis Exacerbates Development of Bisphosphonate-Related Osteonecrosis of the Jaw in Mice. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2022; 37(7): 1400—1410. doi: 10.1002/jbmr.4614